Skip to main content

Drug Safety

That's not my problem - or is it? Multimorbidity in RA RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment. https://t.co/B7WUiysNSE https://t.co/nczmoIBfOb
Dr. John Cush @RheumNow( View Tweet )

Combination biologics in PsA: are we there yet?

Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest

Read Article

Valentine RNL 2025 Review (2.14.2025)

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

Read Article
Janet Pope @Janetbirdope Dispel the #myth #rheumatoid #arthritis is NOT Just a disease of Young and middle aged Elderly PREVALENT #RA Pts and 👇 INCIDENT Pts in >65yrs is skyrocketing 🚀 Need #Rx goals and equitable #Rx Uma Makris #RNL2025 https://t.co/3IsVKTSEyy

Dr. John Cush @RheumNow( View Tweet )

Adela Castro @AdelaCastro222 Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)? -LORA pts tend to present acutely -High inflammatory markers~PMR Like -Seronegative/Decreased titers of RF/CCP @UnaMakris #RNL2025 https://t.co/tLrGBV6P1i https://t.co/53HVvUmrG4
Dr. John Cush @RheumNow( View Tweet )
TheDaoIndex @KDAO2011 Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management @UnaMakris #RNL2025 @RheumNow #GeriRheum… https://t.co/E2WFwfCsWD https://t.co/tKF0OnUFQH
Dr. John Cush @RheumNow( View Tweet )
Obinutuzumab Efficacy in Active Lupus Nephritis A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis. https://t.co/e1cDvJcC9g https://t.co/HUDd1ocAvc
Dr. John Cush @RheumNow( View Tweet )
Eric Dein @ericdeinmd AI models require good Positive Predictive Value (PPV) But: PPV decreases as prevalence decreases - In choosing a successful biologic: Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher J… https://t.co/eAOR0jFmO3 https://t.co/TB6Ecd8nZh
Dr. John Cush @RheumNow( View Tweet )

Will AI put me out of a job?

The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care:

Read Article

Obinutuzumab Efficacy in Active Lupus Nephritis

A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.

Read Article
-HS ttx👇 1. Lifestyle changes: smoking cessation, obesity. 2. Management of comorbidities. 3. 🔍HS- related autoimmune disorders. 4. FDA approved biologics: -Adalimumab (PIONEER 1&2) -Secukinumab (SUNRISE, SUNSHINE) -Bimekizumab (BE HEARD 1&2) "Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1
Adela Castro @AdelaCastro222( View Tweet )
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway @RichardPAConway( View Tweet )
#RNL2025 @RheumNow JAKi in DM: @JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response 145 case reports for tofa, bari, ruxolitinib. Role in helping calcinosis? Pruritu? Brepocitinib (JAK1/TYK2i) study

Eric Dein @ericdeinmd( View Tweet )

#HOT #topic Will #Rx of #PsO PREVENT onset of #PsA Well, maybe 🤔 Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 70% of #psoriatic #arthritis is preceded by #psoriasis Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr
Janet Pope @Janetbirdope( View Tweet )
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush @RheumNow( View Tweet )
Break a leg! Or a #hip #AVN risk occurs even at 1 month of high / moderate dose #glucocorticoids Shown by Michelle Petri @RheumNow #RNL2025 Risk in SLE is likely 👇 #disease #activity And #steroids #SLE #systemic #lupus #erythematosus #steroids https://t.co/4EsQw9tY1u
Janet Pope @Janetbirdope( View Tweet )
Even a #SLE expert who wants all #lupus Pts on No #chronic #prednisone Realizes you can’t get everyone off #glucocorticoids 18% May be on chronic #steroids But she keeps trying to taper Michelle Petri #RNL2025 @RheumNow https://t.co/SNP6Eep731
Janet Pope @Janetbirdope( View Tweet )
M. Petri on Steroids in SLE👇 -Organ damage is higher in AA vs Caucasians-driven by CS -CV risk increase is dose dependent: >10 mg =2x risk >20mg =5x risk -Increase prednisone by 10mg =30% increased risk for organ damage! 🤯 -20mg/day >1m increases risk for… https://t.co/fZVjS7JQBL

Adela Castro @AdelaCastro222( View Tweet )

Wise person once said If you don’t take your medications, THEY DON’T WORK! Shocking 1 in 3 nonadherence with #hydroxychloroquine By drug levels In young Pts with #SLE #lupus Michelle Petri @RheumNow #RNL2025 https://t.co/H5izbnW0qU

Janet Pope @Janetbirdope( View Tweet )

Michele Petri @RheumNow #RNL2025 1 mg of prednisone -> 3% increased risk of damage Taper quickly, withdrawal slowly Make sure background therapy is on - monitor therapy with HCQ levels, early use of additional Rx https://t.co/pjFNcg99ed
Eric Dein @ericdeinmd( View Tweet )
Who’s liable for an incorrect #AI diagnosis or medical advice? @rheumnow #RNL2025 @RADoctor

TheDaoIndex @KDAO2011( View Tweet )

AI models require good Positive Predictive Value (PPV) But: PPV decreases as prevalence decreases - In choosing a successful biologic: Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher J Curtis @RheumNow #RNL2025 https://t.co/SdJ0FHVuSC
Eric Dein @ericdeinmd( View Tweet )
Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management @UnaMakris #RNL2025 @RheumNow #GeriRheum https://t.co/zqEcyg2ejw
TheDaoIndex @KDAO2011( View Tweet )
Can #AI help us determine the 👇 Right drug At Right time Pipe dream? Or to use #artificial #intelligence term ➡️ a #hallucination? garbage in ➡️➡️garbage out Most predictions of drug response are same: multimorbid multiRx failures Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl
Janet Pope @Janetbirdope( View Tweet )
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush @RheumNow( View Tweet )
×